Clinical Study Report - Calidad de Información CFR
Clinical Study Report - Calidad de Información CFR
Clinical Study Report - Calidad de Información CFR
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Sponsor: ISU ABXIS Co.,Ltd<br />
<strong>Study</strong> number: Clotinab_II<br />
Version date: 08-MAR-2006<br />
Name of finished drug : Name of activeingredient : <strong>Study</strong> period :<br />
Clotinab Abciximab 17-MAY-2005 ~ 01-DEC-2005<br />
Safety results<br />
dropped significantly by about 24-27%, <strong>de</strong>pending on the analysis population,<br />
from the baseline. Three ReoPro ® patients experienced major bleeding event. The<br />
major bleeding rate is signifcantly higher in the ReoPro ® group than in the<br />
Clotinab group.<br />
The intention of this clinical study is not <strong>de</strong>signed to compare the efficacy or<br />
safety of Clotinab and ReoPro ® in patients un<strong>de</strong>rgoing the PCI procedure. Thus we<br />
do not make a statement about which treatment is more effective and safer.<br />
Nevertheless we can conclu<strong>de</strong> that Clotinab is effective and safe in preventing the<br />
MACE in patients un<strong>de</strong>rgoing the PCI procedure.<br />
Based on TIMI criteria, no major bleeding occurred in Clotinab, but 3 subjects<br />
(7.50%) experienced major bleeding in ReoPro ® . The number of subjects with<br />
minor bleeding was 11(13.25%) for Clotinab and 5(12.50%) for ReoPro ® . The<br />
number of subjects with clinically insignificant bleeding was 11(13.25%) for<br />
Clotinab and 9(22.50%) for ReoPro ® .<br />
Number of patients with overall bleeding based on TIMI criteria showed no<br />
significant difference between Clotinab and ReoPro ® in each time point. (See Table<br />
12.2:2) However number of patients with major bleeding showed significant<br />
difference(p=0.0326).<br />
No significant results were reported in thrombocytopenia, change in Hb/Hct,<br />
HACA, adverse event, laboratory data.<br />
Serious adverse events were occurred to 7 subjects[{Clotinab 3(3.61%), 95%<br />
exact C.I.(0.75%, 10.20%)}, {ReoPro ® 4(10.00%), 95% exact C.I.(2.79%,<br />
23.66%)}] as follows. Prolongation of existing hospitalization: 2 patients, lifethreatening:<br />
1 subject in Clotinab. Death: 2 subjects, life-threatening: 2 subjects in<br />
ReoPro ® . But Investigators conclu<strong>de</strong>d these 7 cases were not related to study<br />
drug, and there was no significant difference between Clotinab and ReoPro ® in<br />
SAE occurrence rate(P=0.1521).<br />
CSR_Clotinab_II 10<br />
Ver. 1.0_Eng